Altis Biosystems

Executive Summary

Altis Biosystems is a preclinical-stage biotechnology company headquartered in Durham, North Carolina, founded in 2016 with a focus on drug delivery and AI/machine learning. The company's mission is to enable pharmaceutical companies to identify effective compounds earlier in the development process, thereby reducing reliance on animal testing and increasing the success rate of candidates entering clinical trials. By leveraging advanced in vitro models and computational approaches, Altis aims to bridge the gap between preclinical research and human outcomes. While the company remains privately held with no disclosed funding or valuation details, its positioning at the intersection of drug delivery and AI reflects a growing industry trend toward more predictive and ethical drug development tools. Altis operates in a competitive landscape of organ-on-a-chip and in vitro modeling companies but differentiates through its focus on gut and barrier biology. The company's early-stage status implies high risk but also potential for significant impact if its platform gains adoption among pharmaceutical partners.

Upcoming Catalysts (preview)

• Q4 2026Pharmaceutical Partnership or Licensing Deal30% success
• Q2 2027Series A or Series B Funding Round50% success
• Q1 2027Publication of Validation Data in Peer-Reviewed Journal60% success